Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Celcuity, Inc. (NASDAQ:CELC) have received an average rating of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $108.6250.

A number of research analysts have commented on CELC shares. Wells Fargo & Company assumed coverage on Celcuity in a research report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price objective on the stock. Needham & Company LLC boosted their target price on Celcuity from $95.00 to $122.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. HC Wainwright reaffirmed a “neutral” rating and set a $94.00 price target (up from $77.00) on shares of Celcuity in a research note on Monday, November 17th. Wolfe Research reiterated an “outperform” rating and issued a $110.00 price objective on shares of Celcuity in a research report on Thursday. Finally, Jefferies Financial Group lifted their price objective on Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd.

Celcuity Price Performance

Shares of CELC stock opened at $114.22 on Monday. Celcuity has a 1 year low of $7.57 and a 1 year high of $120.32. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74. The firm’s 50 day moving average is $108.80 and its 200-day moving average is $87.35. The firm has a market capitalization of $5.28 billion, a price-to-earnings ratio of -31.12 and a beta of 0.38.

Insider Activity

In other news, Director David Dalvey sold 20,000 shares of Celcuity stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the sale, the director owned 90,000 shares in the company, valued at $10,802,700. The trade was a 18.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 15.78% of the company’s stock.

Hedge Funds Weigh In On Celcuity

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning acquired a new stake in Celcuity during the 2nd quarter worth $177,000. Intech Investment Management LLC lifted its stake in shares of Celcuity by 5.2% in the 2nd quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock valued at $198,000 after purchasing an additional 734 shares during the period. Rhumbline Advisers boosted its position in shares of Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after purchasing an additional 503 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Celcuity during the second quarter worth $169,000. Finally, Saturn V Capital Management LP grew its stake in shares of Celcuity by 8.4% during the second quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock worth $15,827,000 after purchasing an additional 91,843 shares during the period. 63.33% of the stock is owned by institutional investors.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.